BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 29440182)

  • 1. Shedding Light on
    Hollon TC; Orringer DA
    Clin Cancer Res; 2018 Jun; 24(11):2467-2469. PubMed ID: 29440182
    [No Abstract]   [Full Text] [Related]  

  • 2. Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the
    Uckermann O; Juratli TA; Galli R; Conde M; Wiedemuth R; Krex D; Geiger K; Temme A; Schackert G; Koch E; Steiner G; Kirsch M
    Clin Cancer Res; 2018 Jun; 24(11):2530-2538. PubMed ID: 29259030
    [No Abstract]   [Full Text] [Related]  

  • 3. Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress.
    Lenting K; Khurshed M; Peeters TH; van den Heuvel CNAM; van Lith SAM; de Bitter T; Hendriks W; Span PN; Molenaar RJ; Botman D; Verrijp K; Heerschap A; Ter Laan M; Kusters B; van Ewijk A; Huynen MA; van Noorden CJF; Leenders WPJ
    FASEB J; 2019 Jan; 33(1):557-571. PubMed ID: 30001166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
    Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
    Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of IDH-mutant gliomas with non-canonical IDH mutation.
    Poetsch L; Bronnimann C; Loiseau H; Frénel JS; Siegfried A; Seizeur R; Gauchotte G; Cappellen D; Carpentier C; Figarella-Branger D; Eimer S; Meyronet D; Ducray F;
    J Neurooncol; 2021 Jan; 151(2):279-286. PubMed ID: 33205355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH1 and IDH2 mutations in gliomas.
    Cohen AL; Holmen SL; Colman H
    Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Metabolomic Analysis of IDH1
    Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
    Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High levels of TIMP1 are associated with increased extracellular matrix stiffness in isocitrate dehydrogenase 1-wild type gliomas.
    Luo CH; Shi Y; Liu YQ; Liu Q; Mao M; Luo M; Yang KD; Wang WY; Chen C; Niu Q; Yan ZX; Miao JY; Zhang XN; Zeng H; Li L; Bian XW; Ping YF
    Lab Invest; 2022 Dec; 102(12):1304-1313. PubMed ID: 35882906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
    Malueka RG; Dwianingsih EK; Bayuangga HF; Panggabean AS; Argo IW; Donurizki AD; Shaleh S; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2287-2295. PubMed ID: 32856857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
    Liu FM; Gao YF; Kong Y; Guan Y; Zhang J; Li SH; Ye D; Wen W; Zuo C; Hua W
    BMC Cancer; 2021 Jan; 21(1):83. PubMed ID: 33472598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis.
    Di Nunno V; Franceschi E; Tosoni A; Gatto L; Maggio I; Lodi R; Angelini D; Bartolini S; Brandes AA
    Adv Ther; 2022 Jan; 39(1):165-177. PubMed ID: 34853984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expanding the spectrum of IDH1 mutations in gliomas.
    Gupta R; Flanagan S; Li CC; Lee M; Shivalingham B; Maleki S; Wheeler HR; Buckland ME
    Mod Pathol; 2013 May; 26(5):619-25. PubMed ID: 23307057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
    Hirano M; Ohka F; Maeda S; Chalise L; Yamamichi A; Aoki K; Kato A; Tanahashi K; Motomura K; Nishimura Y; Hara M; Shinjo K; Kondo Y; Wakabayashi T; Natsume A
    Brain Tumor Pathol; 2018 Apr; 35(2):97-105. PubMed ID: 29460200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
    Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
    J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determining IDH-Mutational Status in Gliomas Using IDH1-R132H Antibody and Polymerase Chain Reaction.
    Gondim DD; Gener MA; Curless KL; Cohen-Gadol AA; Hattab EM; Cheng L
    Appl Immunohistochem Mol Morphol; 2019; 27(10):722-725. PubMed ID: 30358614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.